These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 27206567)

  • 41. The Serotonin 2C Receptor Agonist Lorcaserin Attenuates Intracranial Self-Stimulation and Blocks the Reward-Enhancing Effects of Nicotine.
    Zeeb FD; Higgins GA; Fletcher PJ
    ACS Chem Neurosci; 2015 Jul; 6(7):1231-40. PubMed ID: 25781911
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The 5-HT
    Campbell EJ; Bonomo Y; Pastor A; Collins L; Norman A; Galettis P; Johnstone J; Lawrence AJ
    Pharmacol Res Perspect; 2021 May; 9(3):e00767. PubMed ID: 33929084
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lorcaserin for weight loss: insights into US Food and Drug Administration approval.
    Miller LE
    J Acad Nutr Diet; 2013 Jan; 113(1):25-30. PubMed ID: 23260720
    [No Abstract]   [Full Text] [Related]  

  • 44. 5-HT(2C) receptor agonists and the control of appetite.
    Halford JC; Harrold JA
    Handb Exp Pharmacol; 2012; (209):349-56. PubMed ID: 22249823
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Discovery and development of 5-HT(₂C) receptor agonists for obesity: is there light at the end of the tunnel?
    Miller KJ; Wacker DA
    Future Med Chem; 2010 Dec; 2(12):1761-75. PubMed ID: 21428799
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chemistry, Analysis, Pharmacokinetics and Pharmacodynamics Aspects of Lorcaserin, a Selective Serotonin 5-HT2C Receptor Agonist: An Update.
    Sharma S; Aware KS; Hatware K; Patil K
    Mini Rev Med Chem; 2020; 20(9):768-778. PubMed ID: 30961494
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of lorcaserin for the treatment of obesity.
    Berlie HD; Hurren KM
    Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):1053-9. PubMed ID: 23802690
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mechanisms of Action of Cassiae Semen for Weight Management: A Computational Molecular Docking Study of Serotonin Receptor 5-HT2C.
    Yuen H; Hung A; Yang AWH; Lenon GB
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32079105
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Drug management of obesity--efficacy versus safety.
    Astrup A
    N Engl J Med; 2010 Jul; 363(3):288-90. PubMed ID: 20647205
    [No Abstract]   [Full Text] [Related]  

  • 50. Characterization of the discriminative stimulus effects of lorcaserin in rats.
    Serafine KM; Rice KC; France CP
    J Exp Anal Behav; 2016 Sep; 106(2):107-16. PubMed ID: 27640338
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Coadministration of lorcaserin and phentermine for weight management: A 12-week, randomized, pilot safety study.
    Smith SR; Garvey WT; Greenway FL; Zhou S; Fain R; Pilson R; Fujioka K; Aronne LJ
    Obesity (Silver Spring); 2017 May; 25(5):857-865. PubMed ID: 28440045
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Circulating total and intact GDF-15 levels are not altered in response to weight loss induced by liraglutide or lorcaserin treatment in humans with obesity.
    Valenzuela-Vallejo L; Chrysafi P; Bello-Ramos J; Bsata S; Mantzoros CS
    Metabolism; 2022 Aug; 133():155237. PubMed ID: 35700837
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Repeated 7-Day Treatment with the 5-HT
    Banks ML; Negus SS
    Neuropsychopharmacology; 2017 Apr; 42(5):1082-1092. PubMed ID: 27857126
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of lorcaserin on cardiometabolic risk factors in overweight and obese patients: A systematic review and meta-analysis.
    Kuo HH; Wang KT; Lee YH; Lin PL; Liu ME; Lin CY; Liu LY
    J Clin Pharm Ther; 2020 Feb; 45(1):35-44. PubMed ID: 31544267
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adjunctive effect of the serotonin 5-HT
    Sierra S; Lippold KM; Stevens DL; Poklis JL; Dewey WL; González-Maeso J
    Neuropharmacology; 2020 May; 167():107949. PubMed ID: 31987863
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic Potential of 5-HT2C Receptor Agonists for Addictive Disorders.
    Higgins GA; Fletcher PJ
    ACS Chem Neurosci; 2015 Jul; 6(7):1071-88. PubMed ID: 25870913
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of pimavanserin and lorcaserin on alcohol self-administration and reinstatement in male and female rats.
    Fletcher PJ; Li Z; Ji X; Higgins GA; Funk D; Lê AD
    Neuropharmacology; 2022 Sep; 215():109150. PubMed ID: 35644487
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of Selective 5-HT
    Silenieks LB; Carroll NK; Van Niekerk A; Van Niekerk E; Taylor C; Upton N; Higgins GA
    ACS Chem Neurosci; 2019 Jul; 10(7):3284-3295. PubMed ID: 31082204
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Health-related quality of life in randomized controlled trials of lorcaserin for obesity management: what mediates improvement?
    Kolotkin RL; Crosby RD; Wang Z
    Clin Obes; 2017 Dec; 7(6):347-353. PubMed ID: 28815987
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New obesity agents: lorcaserin and phentermine/topiramate.
    Fleming JW; McClendon KS; Riche DM
    Ann Pharmacother; 2013; 47(7-8):1007-16. PubMed ID: 23800750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.